Golara Honari, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Honari’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A124118 · Current
Licensed to practise in California · since 2013 · expires 2027-01-31 · Iran University of Medical Sciences and Health Services.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$31,720
Medicare paid this office $31,720 for 211 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 123 | $14,066 | $86 |
| Short return visit (20+ min) | 54 | $3,753 | $57 |
| Destruction of precancer skin growth, 1 growth | 50 | $2,711 | $44 |
| Long return visit (40+ min) | 15 | $2,367 | $148 |
| Destruction of skin growth, 1-14 growths | 33 | $2,120 | $64 |
See all 11 services
| Return visit (30+ min) | 123 | $14,066 | $86 |
| Short return visit (20+ min) | 54 | $3,753 | $57 |
| Destruction of precancer skin growth, 1 growth | 50 | $2,711 | $44 |
| Long return visit (40+ min) | 15 | $2,367 | $148 |
| Destruction of skin growth, 1-14 growths | 33 | $2,120 | $64 |
| New patient visit (30+ min) | 17 | $1,100 | $65 |
| Biopsy of related skin growth, first growth | 29 | $870 | $26 |
| New patient visit (15+ min) | 13 | $540 | $42 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 30 | $505 | $15 |
| Short return visit | 14 | $488 | $35 |
| Destruction of precancer skin growth, 2-14 growths | 41 | $338 | $2 |
Procedures Medicare counted
| Removal of skin lesions | 118 | More than 76% of doctors who do this |
| Skin biopsy | 65 | More than 71% of doctors who do this |
Who their Medicare patients are
211 Original Medicare patients in 2024. Average age 73 · Under 65 7% · 85 and older 6% · Women 60% · Also on Medicaid 16% · Health risk score 1.10. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 61% · Coronary heart disease 22% · Chronic kidney disease 18% · Atrial fibrillation 18% · Depression 18% · Diabetes 17% · Cancer 15% · Heart failure 10% · Stroke 6% · COPD 5%.
The office billed $143,174, Medicare allowed $43,037 and paid $31,720; for 675 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 211 | 675 | 73 | 1.10 | $143,174 | $31,720 |
| 2023 | 192 | 610 | 73 | 1.09 | $123,700 | $26,404 |
| 2022 | 181 | 593 | 73 | 1.22 | $123,798 | $24,130 |
| 2021 | 236 | 694 | 73 | 1.15 | $141,114 | $29,738 |
| 2020 | 304 | 901 | 74 | 1.24 | $322,056 | $36,572 |
| 2019 | 436 | 1,554 | 74 | 1.25 | $777,816 | $81,434 |
| 2018 | 450 | 1,466 | 73 | 1.31 | $636,625 | $78,422 |
| 2017 | 437 | 1,524 | 74 | 1.10 | $632,198 | $86,593 |
| 2016 | 386 | 1,113 | 73 | 1.18 | $367,072 | $65,628 |
| 2015 | 157 | 377 | 72 | 1.31 | $120,653 | $19,401 |
| 2013 | 131 | 255 | 72 | 1.40 | $48,121 | $7,152 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 107 | $11,313 | $86 |
| Short return visit (20+ min) | 61 | $3,849 | $57 |
| Destruction of precancer skin growth, 1 growth | 46 | $2,782 | $50 |
| Biopsy of related skin growth, first growth | 48 | $1,550 | $27 |
| Destruction of skin growth, 1-14 growths | 17 | $1,115 | $62 |
| New patient visit (30+ min) | 14 | $1,044 | $75 |
| Biopsy of related skin growth, each additional growth | 17 | $696 | $20 |
| New patient visit (15+ min) | 19 | $611 | $32 |
| Destruction of precancer skin growth, 2-14 growths | 35 | $333 | $2 |
2022: 9 services
| Return visit (30+ min) | 107 | $11,538 | $82 |
| Short return visit (20+ min) | 64 | $3,627 | $51 |
| Destruction of precancer skin growth, 1 growth | 47 | $2,630 | $45 |
| Destruction of skin growth, 1-14 growths | 20 | $1,233 | $56 |
| Biopsy of related skin growth, first growth | 37 | $1,016 | $24 |
| New patient visit (30+ min) | 11 | $820 | $75 |
| New patient visit (15+ min) | 17 | $721 | $42 |
| Biopsy of related skin growth, each additional growth | 16 | $539 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 39 | $309 | $2 |
2021: 11 services
| Return visit (30+ min) | 124 | $12,242 | $82 |
| Short return visit (20+ min) | 88 | $6,084 | $54 |
| Destruction of precancer skin growth, 1 growth | 55 | $2,831 | $42 |
| Long return visit (40+ min) | 14 | $1,776 | $118 |
| Biopsy of related skin growth, first growth | 52 | $1,383 | $26 |
| New patient visit (15+ min) | 26 | $1,076 | $41 |
| Destruction of skin growth, 1-14 growths | 16 | $1,051 | $58 |
| New patient visit (30+ min) | 13 | $908 | $70 |
| Biopsy of related skin growth, each additional growth | 18 | $447 | $20 |
| Short return visit | 12 | $412 | $32 |
| Destruction of precancer skin growth, 2-14 growths | 38 | $296 | $2 |
2020: 11 services
| Short return visit (20+ min) | 170 | $10,955 | $47 |
| Return visit (30+ min) | 125 | $9,974 | $75 |
| Destruction of precancer skin growth, 1 growth | 72 | $2,999 | $39 |
| Destruction of skin growth, 1-14 growths | 33 | $2,657 | $81 |
| Biopsy of related skin growth, first growth | 60 | $2,089 | $33 |
| New patient visit (15+ min) | 28 | $1,365 | $49 |
| Biopsy of related skin growth, each additional growth | 29 | $1,063 | $26 |
| Punch biopsy, first skin growth | 12 | $696 | $54 |
| Destruction of precancer skin growth, 2-14 growths | 52 | $534 | $3 |
| Short return visit | 17 | $440 | $26 |
| Telehealth originating site facility fee | 11 | $234 | $21 |
2019: 11 services
| Return visit (30+ min) | 239 | $27,608 | $91 |
| Biopsy of related skin growth, first growth | 122 | $10,407 | $73 |
| Short return visit (20+ min) | 138 | $9,947 | $59 |
| Destruction of skin growth, 1-14 growths | 64 | $6,695 | $94 |
| Destruction of precancer skin growth, 1 growth | 124 | $6,290 | $42 |
| New patient visit (30+ min) | 64 | $5,348 | $84 |
| New patient visit (15+ min) | 60 | $3,539 | $59 |
| Biopsy of related skin growth, each additional growth | 48 | $3,490 | $45 |
| Destruction of precancer skin growth, 2-14 growths | 91 | $1,927 | $5 |
| Punch biopsy, first skin growth | 12 | $932 | $78 |
| Injection into skin growth, 1-7 growths | 13 | $608 | $38 |
2018: 11 services
| Return visit (30+ min) | 222 | $24,756 | $86 |
| Biopsy of single growth of skin and/or tissue | 127 | $10,366 | $72 |
| Short return visit (20+ min) | 139 | $9,226 | $54 |
| New patient visit (30+ min) | 76 | $7,166 | $94 |
| Destruction of precancer skin growth, 1 growth | 124 | $6,595 | $45 |
| Destruction of skin growth, 1-14 growths | 53 | $6,076 | $96 |
| New patient visit (15+ min) | 64 | $3,529 | $55 |
| Biopsy of each additional growth of skin and/or tissue | 48 | $1,969 | $27 |
| Destruction of precancer skin growth, 2-14 growths | 91 | $1,528 | $4 |
| Long return visit (40+ min) | 12 | $1,359 | $97 |
| Short return visit | 16 | $682 | $43 |
2017: 10 services
| Return visit (30+ min) | 174 | $21,623 | $92 |
| Short return visit (20+ min) | 150 | $11,148 | $62 |
| Biopsy of single growth of skin and/or tissue | 118 | $10,944 | $82 |
| New patient visit (30+ min) | 94 | $8,448 | $90 |
| New patient visit (15+ min) | 120 | $7,968 | $66 |
| Destruction of skin growth, 1-14 growths | 65 | $7,174 | $97 |
| Destruction of precancer skin growth, 1 growth | 105 | $5,794 | $46 |
| Destruction of precancer skin growth, 2-14 growths | 79 | $1,921 | $5 |
| Biopsy of each additional growth of skin and/or tissue | 38 | $1,648 | $28 |
| Short return visit | 35 | $1,504 | $40 |
2016: 13 services
| New patient visit (15+ min) | 206 | $12,984 | $63 |
| Short return visit (20+ min) | 132 | $11,104 | $62 |
| Return visit (30+ min) | 81 | $9,510 | $88 |
| Biopsy of single growth of skin and/or tissue | 58 | $5,549 | $90 |
| Destruction of precancer skin growth, 1 growth | 87 | $4,634 | $48 |
| New patient visit (30+ min) | 35 | $3,393 | $97 |
| Destruction of skin growth, 1-14 growths | 21 | $2,675 | $96 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 19 | $2,310 | $92 |
| Short return visit | 25 | $1,334 | $39 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 14 | $1,212 | $76 |
| Destruction of precancer skin growth, 2-14 growths | 65 | $1,064 | $5 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $589 | $29 |
| New patient visit (10+ min) | 12 | $501 | $42 |
2015: 6 services
| New patient visit (15+ min) | 117 | $8,039 | $69 |
| Short return visit (20+ min) | 24 | $2,222 | $67 |
| Biopsy of single growth of skin and/or tissue | 19 | $2,023 | $101 |
| Destruction of precancer skin growth, 1 growth | 30 | $1,697 | $53 |
| Short return visit (20+ min) | 13 | $633 | $45 |
| Destruction of precancer skin growth, 2-14 growths | 21 | $519 | $5 |
2013: 7 services
| New patient visit (15+ min) | 56 | $1,807 | $32 |
| Short return visit (20+ min) | 46 | $1,591 | $32 |
| Biopsy of single growth of skin and/or tissue | 41 | $1,167 | $28 |
| Destruction of skin growth, 1-14 growths | 17 | $867 | $48 |
| Destruction of precancer skin growth, 1 growth | 14 | $444 | $32 |
| Biopsy of each additional growth of skin and/or tissue | 15 | $347 | $18 |
| Short return visit | 13 | $250 | $18 |
Medicaid work
$447 in 2021
Medicaid paid $447 for 15 billed services this clinician did in 2021, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 15 | $447 |
| 2021 | 15 | 1 | 15 | $447 |
| 2020 | 40 | 1 | 14 | $1,242 |
| 2019 | 12 | 1 | 12 | $529 |
| 2018 | 28 | 1 | 14 | $743 |
See the largest Medicaid services in earlier years
2020
| Short return visit (20+ min) | 40 | $1,242 |
2019
| Short return visit (20+ min) | 12 | $529 |
2018
| Short return visit (20+ min) | 28 | $743 |
Drugs they prescribed that Part D paid
$392,206
Pharmacies billed $392,206 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 487) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
418 generic and 69 brand-name prescriptions · $392,206 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 14 | $62,446 | $4,460 |
| Tacrolimus | 18 | $2,760 | $153 |
| Fluorouracil | 30 | $1,884 | $63 |
| Fluocinonide | 49 | $1,400 | $29 |
| Betamethasone Dipropionate | 11 | $979 | $89 |
See all 12 drugs
| Dupixent | 14 | $62,446 | $4,460 |
| Tacrolimus | 18 | $2,760 | $153 |
| Fluorouracil | 30 | $1,884 | $63 |
| Fluocinonide | 49 | $1,400 | $29 |
| Betamethasone Dipropionate | 11 | $979 | $89 |
| Ciclopirox | 24 | $669 | $28 |
| Clobetasol Propionate | 18 | $648 | $36 |
| Triamcinolone Acetonide | 44 | $583 | $13 |
| Ketoconazole | 33 | $515 | $16 |
| Minoxidil | 16 | $359 | $22 |
| Mupirocin | 19 | $186 | $10 |
| Hydrocortisone | 25 | $148 | $6 |
Year by year
| 2024 | 487 | 159 | 0% (0) | 14% | $392,206 |
| 2023 | 391 | 134 | 0% (0) | 16% | $422,925 |
| 2022 | 514 | 152 | None | 12% | $382,902 |
| 2021 | 504 | 160 | 0% (0) | 16% | $482,912 |
| 2020 | 596 | 198 | 0% (0) | 12% | $285,781 |
| 2019 | 800 | 265 | 0% (0) | 17% | $351,103 |
| 2018 | 780 | 267 | 0% (0) | 13% | $233,723 |
| 2017 | 676 | 254 | None | 11% | $159,643 |
| 2016 | 570 | 219 | 0% (0) | 17% | $88,416 |
| 2015 | 536 | 237 | 0% (0) | None | $113,737 |
| 2014 | 431 | 190 | None | 21% | $61,126 |
| 2013 | 311 | 158 | None | None | $39,940 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Humira | 13 | $105,105 | $8,085 |
| Dupixent | 19 | $101,278 | $5,330 |
| Tacrolimus | 11 | $3,630 | $330 |
| Fluocinonide | 37 | $1,839 | $50 |
| Fluorouracil | 23 | $1,749 | $76 |
| Clindamycin Phosphate | 15 | $785 | $52 |
| Tretinoin | 11 | $772 | $70 |
| Ciclopirox | 15 | $618 | $41 |
| Nystatin | 14 | $527 | $38 |
| Clobetasol Propionate | 14 | $517 | $37 |
| Ketoconazole | 32 | $492 | $15 |
| Ciclopirox | 11 | $396 | $36 |
| Triamcinolone Acetonide | 27 | $277 | $10 |
| Hydrocortisone | 34 | $186 | $5 |
| Mupirocin | 17 | $160 | $9 |
2022: 13 drugs
| Humira | 15 | $115,177 | $7,678 |
| Dupixent | 16 | $58,632 | $3,664 |
| Tacrolimus | 36 | $6,050 | $168 |
| Fluocinonide | 45 | $2,701 | $60 |
| Fluorouracil | 22 | $2,432 | $111 |
| Betamethasone Dipropionate | 21 | $1,619 | $77 |
| Ketoconazole | 50 | $798 | $16 |
| Triamcinolone Acetonide | 45 | $622 | $14 |
| Ciclopirox | 13 | $494 | $38 |
| Nystatin | 13 | $407 | $31 |
| Hydrocortisone | 40 | $306 | $8 |
| Mupirocin | 21 | $247 | $12 |
| Hydroxyzine | 12 | $72 | $6 |
2021: 13 drugs
| Humira | 15 | $151,114 | $10,074 |
| Dupixent | 14 | $47,401 | $3,386 |
| Tacrolimus | 20 | $2,990 | $150 |
| Fluocinonide | 51 | $2,988 | $59 |
| Metronidazole | 11 | $1,739 | $158 |
| Fluorouracil | 20 | $1,675 | $84 |
| Ketoconazole | 47 | $772 | $16 |
| Clobetasol Propionate | 15 | $696 | $46 |
| Triamcinolone Acetonide | 49 | $665 | $14 |
| Ciclopirox | 19 | $647 | $34 |
| Mupirocin | 30 | $318 | $11 |
| Hydrocortisone | 45 | $231 | $5 |
| Acyclovir | 16 | $152 | $9 |
2020: 17 drugs
| Humira | 11 | $65,406 | $5,946 |
| Dupixent | 13 | $40,676 | $3,129 |
| Fluorouracil | 39 | $3,539 | $91 |
| Fluocinonide | 56 | $3,516 | $63 |
| Clindamycin Phosphate | 26 | $2,108 | $81 |
| Metronidazole | 13 | $1,415 | $109 |
| Tretinoin | 14 | $1,344 | $96 |
| Triamcinolone Acetonide | 65 | $1,229 | $19 |
| Tacrolimus | 11 | $1,216 | $111 |
| Clobetasol Propionate | 18 | $862 | $48 |
| Ciclopirox | 18 | $658 | $37 |
| Ketoconazole | 56 | $648 | $12 |
| Fluocinolone Acetonide | 12 | $637 | $53 |
| Hydrocortisone | 85 | $447 | $5 |
| Mupirocin | 28 | $291 | $10 |
| Acyclovir | 12 | $95 | $8 |
| Gabapentin | 14 | $60 | $4 |
2019: 15 drugs
| Humira | 13 | $71,972 | $5,536 |
| Cosentyx Pen (2 Pens) | 13 | $61,700 | $4,746 |
| Fluorouracil | 86 | $11,491 | $134 |
| Tacrolimus | 31 | $7,312 | $236 |
| Fluocinonide | 71 | $4,486 | $63 |
| Metronidazole | 30 | $3,737 | $125 |
| Clobetasol Propionate | 30 | $2,204 | $73 |
| Clindamycin Phosphate | 31 | $2,104 | $68 |
| Triamcinolone Acetonide | 107 | $1,582 | $15 |
| Ketoconazole | 72 | $943 | $13 |
| Ciclopirox | 24 | $672 | $28 |
| Ciclopirox | 14 | $667 | $48 |
| Mupirocin | 26 | $499 | $19 |
| Hydrocortisone | 82 | $444 | $5 |
| Gabapentin | 24 | $154 | $6 |
2018: 18 drugs
| Humira | 13 | $61,120 | $4,702 |
| Fluorouracil | 70 | $7,827 | $112 |
| Clobetasol Propionate | 43 | $5,181 | $120 |
| Fluocinonide | 59 | $3,623 | $61 |
| Tacrolimus | 16 | $3,145 | $197 |
| Metronidazole | 18 | $2,718 | $151 |
| Clindamycin Phosphate | 36 | $2,497 | $69 |
| Triamcinolone Acetonide | 118 | $1,969 | $17 |
| Calcipotriene | 11 | $1,758 | $160 |
| Adapalene | 11 | $888 | $81 |
| Ketoconazole | 54 | $815 | $15 |
| Hydrocortisone | 91 | $507 | $6 |
| Ciclopirox | 18 | $493 | $27 |
| Mupirocin | 29 | $329 | $11 |
| Clotrimazole | 16 | $288 | $18 |
| Gabapentin | 17 | $202 | $12 |
| Cephalexin | 12 | $85 | $7 |
| Prednisone | 11 | $45 | $4 |
2017: 19 drugs
| Humira | 13 | $59,491 | $4,576 |
| Clobetasol Propionate | 80 | $10,850 | $136 |
| Tacrolimus | 12 | $5,356 | $446 |
| Fluorouracil | 32 | $4,198 | $131 |
| Econazole Nitrate | 23 | $3,727 | $162 |
| Acitretin | 16 | $3,041 | $190 |
| Metronidazole | 15 | $2,508 | $167 |
| Fluocinonide | 31 | $2,424 | $78 |
| Clindamycin Phosphate | 21 | $1,976 | $94 |
| Triamcinolone Acetonide | 58 | $749 | $13 |
| Ciclopirox | 24 | $587 | $24 |
| Ketoconazole | 29 | $489 | $17 |
| Hydrocortisone | 77 | $463 | $6 |
| Ciclopirox | 13 | $386 | $30 |
| Gabapentin | 26 | $249 | $10 |
| Clotrimazole | 12 | $199 | $17 |
| Mupirocin | 22 | $197 | $9 |
| Hydroxyzine | 17 | $182 | $11 |
| Acyclovir | 13 | $106 | $8 |
2016: 18 drugs
| Clobetasol Propionate | 73 | $13,444 | $184 |
| Elidel | 16 | $5,479 | $342 |
| Acitretin | 14 | $3,958 | $283 |
| Econazole Nitrate | 27 | $3,606 | $134 |
| Fluorouracil | 22 | $2,714 | $123 |
| Metronidazole | 13 | $2,594 | $200 |
| Fluocinonide | 26 | $2,122 | $82 |
| Clindamycin Phosphate | 25 | $1,551 | $62 |
| Triamcinolone Acetonide | 42 | $640 | $15 |
| Ketoconazole | 30 | $545 | $18 |
| Ciclopirox | 11 | $351 | $32 |
| Hydrocortisone | 41 | $288 | $7 |
| Gabapentin | 25 | $264 | $11 |
| Clotrimazole | 12 | $254 | $21 |
| Mupirocin | 25 | $229 | $9 |
| Prednisone | 20 | $148 | $7 |
| Cephalexin | 13 | $133 | $10 |
| Acyclovir | 19 | $112 | $6 |
2015: 14 drugs
| Clobetasol Propionate | 79 | $17,687 | $224 |
| Fluorouracil | 60 | $7,801 | $130 |
| Metronidazole | 20 | $4,736 | $237 |
| Elidel | 18 | $3,981 | $221 |
| Vectical | 20 | $3,930 | $196 |
| Fluocinolone Acetonide | 14 | $3,910 | $279 |
| Fluocinonide | 35 | $3,746 | $107 |
| Clindamycin Phosphate | 17 | $2,051 | $121 |
| Mupirocin | 34 | $865 | $25 |
| Triamcinolone Acetonide | 27 | $553 | $20 |
| Hydrocortisone | 28 | $343 | $12 |
| Prednisone | 17 | $239 | $14 |
| Terbinafine | 21 | $190 | $9 |
| Cephalexin | 11 | $154 | $14 |
2014: 9 drugs
| Clobetasol Propionate | 91 | $6,331 | $70 |
| Elidel | 23 | $5,130 | $223 |
| Metronidazole | 17 | $4,213 | $248 |
| Fluorouracil | 27 | $3,191 | $118 |
| Fluocinonide | 37 | $2,560 | $69 |
| Mupirocin | 30 | $902 | $30 |
| Triamcinolone Acetonide | 24 | $815 | $34 |
| Hydrocortisone | 20 | $312 | $16 |
| Prednisone | 17 | $251 | $15 |
2013: 7 drugs
| Fluorouracil | 16 | $2,111 | $132 |
| Clobetasol Propionate | 49 | $1,411 | $29 |
| Triamcinolone Acetonide | 37 | $665 | $18 |
| Ketoconazole | 26 | $584 | $22 |
| Mupirocin | 15 | $320 | $21 |
| Hydrocortisone | 19 | $207 | $11 |
| Prednisone | 16 | $80 | $5 |
Money from drug and device companies
$1,250 in 2024
| 2024 | 1 | 1 | $1,250 | $1,250 |
| 2023 | 1 | 2 | None | $31 |
| 2019 | 1 | 1 | None | $1,825 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | Dupixent | $1,250 | 1 payment
|
See the published payment
| Genzyme | Paid to speak or teach · 2024-01-29 | Dupixent | $1,250 |
See earlier years (2023, 2019)
2023: $31
| Pfizer | Cibinqo | $31 | 2 payments
|
2019: $1,825
| Allerderm Laboratories | None | $1,825 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · Assessment of New Head and Neck Eruption in Patients With Atopic Dermatitis During Treatment With Duplimab · 2023 | Their institution | $616,471 |
| Regeneron Pharmaceuticals, Inc. · Assessment of New Head and Neck Eruption in Patients With Atopic Dermatitis During Treatment With Duplimab · 2025 | Their institution | $462,180 |
| Regeneron Pharmaceuticals, Inc. · Assessment of New Head and Neck Eruption in Patients With Atopic Dermatitis During Treatment With Duplimab · 2024 | Their institution | $392,809 |
| Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-To-Severe Atopic Hand and Foot Dermatitis · 2022 | Their institution | $44,336 |
| Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2025 | This clinician | $3,427 |
| AbbVie Inc. · 2020 | This clinician | $2,500 |
| Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-To-Severe Atopic Hand and Foot Dermatitis · 2023 | Their institution | $1,431 |
| Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-To-Severe Atopic Hand and Foot Dermatitis · 2023 | This clinician | $1,384 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1730359118
- Licence
- CA A124118, OH 57-003911California A124118: Current · expires 2027-01-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-03-03
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 440 Broadway St Fl B4, Redwood City, CA, 94063